Sun Pharma Advanced Research Company (SPARC) has registered poor performance during the fourth quarter ended March 2014 and it incurred a net loss of Rs. 2.51 crore as against a net profit of Rs. 44.04 crore in the similar quarter of last year mainly due to lower sales and higher costs. Its net sales declined sharply by 40.7 per cent to Rs. 42.57 crore from Rs. 71.83 crore. Its clinical trials and professional charges increased significantly to Rs. 17.78 crore from Rs. 9.38 crore and the cost of license and fees went up to Rs. 13.72 crore from Rs. 0.23 crore.
For the full year ended March 2014, SPARC's net sales increased by 91.4 per cent to Rs. 167.03 crore from Rs. 87.28 crore in the previous year. It turned the corner and achieved net profit of Rs. 30.32 crore as compared to net loss of Rs. 22.49 crore due to higher sales and other income. Its other income amounted to Rs. 10 crore as against Rs. 1.62 crore in the previous year. The company generated positive EPS of Rs. 1.28 as compared to negative Rs. 1.03 in the last year.